Shenzhen base for world's first gene therapy

摘要

Gendicine, a recombinant adenoviral-p53 agent primarily for head and neck cancer, was the world's first gene therapy product to be approved for commercial production when it was given the go ahead by China's State Food and Drug Administration (SFDA) in January 2004. That it was developed in Shenzhen reflects the Shenzhen economic zone's high-technology research and development strategy.